Question Everything. See who's reporting it.

Experimental Drug Shows Promise in Preventing Pancreatic Cancer in High-Risk Patients

Source: Good News Network

The story in brief

An experimental drug generated immune responses against pancreatic cancer in high-risk individuals, with none developing cancer or high-risk lesions after 16.5 months of follow-up. The phase 1 trial, conducted between April 2022 and February 2026, involved 20 participants with a hereditary predisposition and pancreatic abnormalities. KRAS mutations, common in pancreatic cancers, were targeted by the treatment, which showed mild to moderate side effects.

NEWXFree on Android and iPhone. Open in NEWX